Related Experiment Video
Updated: Mar 11, 2026
11:13
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
9.3K
GPC-3 in hepatocellular carcinoma: current perspectives
Yongle Wu1, Hui Liu2, Huiguo Ding1
1Department of Gastroenterology and Hepatology.
Journal of Hepatocellular Carcinoma
|November 24, 2016
Summary
Glypican-3 (GPC3) is elevated in liver cancer but not in normal tissues, making it a key biomarker for hepatocellular carcinoma (HCC) diagnosis and prognosis. Targeting GPC3 shows promise for novel HCC immunotherapies.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Glypican-3 (GPC3), a cell membrane-associated heparan sulfate proteoglycan, is significantly overexpressed in hepatocellular carcinoma (HCC).
- GPC3 is notably absent in normal liver tissues and benign liver lesions, establishing its specificity for HCC.
- Elevated GPC3 levels in serum or liver tissue correlate with a poor prognosis for HCC patients.
Approach:
- GPC3 serves as a diagnostic biomarker for identifying HCC.
- GPC3 is utilized as an HCC-specific positron emission tomography probe for imaging.
- Research is exploring GPC3's role in promoting HCC growth and metastasis via Wnt signaling.
Key Points:
- GPC3 overexpression is a hallmark of hepatocellular carcinoma.
- GPC3's absence in normal and benign liver tissues enhances its diagnostic utility.
- GPC3 actively drives HCC progression and metastasis through specific signaling pathways.
Conclusions:
- GPC3 is a valuable biomarker for HCC diagnosis and prognosis.
- Targeting GPC3, using agents like GC33, HN3, and YP7, presents potential immunotherapeutic strategies for HCC treatment.
